Middle East Pharmaceutical Industries Company (TADAWUL: 4016)
Saudi Arabia
· Delayed Price · Currency is SAR
118.60
-1.60 (-1.33%)
Dec 19, 2024, 3:19 PM AST
Middle East Pharmaceutical Industries Company Income Statement
Financials in millions SAR. Fiscal year is January - December.
Millions SAR. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | 387.18 | 338.44 | 302.66 | 287.22 | 301.66 |
| Revenue Growth (YoY) | 31.63% | 11.82% | 5.38% | -4.79% | - |
| Cost of Revenue | 143.25 | 131.4 | 119.21 | 113.47 | 126.25 |
| Gross Profit | 243.93 | 207.04 | 183.45 | 173.76 | 175.41 |
| Selling, General & Admin | 150.51 | 130.93 | 113.73 | 97.74 | 92.87 |
| Other Operating Expenses | -0.35 | 0.09 | 0.18 | -0.14 | 0.05 |
| Operating Expenses | 152.51 | 129.51 | 114.04 | 97.6 | 94.92 |
| Operating Income | 91.42 | 77.53 | 69.41 | 76.16 | 80.49 |
| Interest Expense | -4.65 | -5.75 | -4.73 | -1.87 | -1.2 |
| Currency Exchange Gain (Loss) | -0.47 | -0.47 | 0.27 | - | - |
| Other Non Operating Income (Expenses) | - | - | - | -1.08 | -1.48 |
| EBT Excluding Unusual Items | 86.3 | 71.31 | 64.95 | 73.22 | 77.81 |
| Gain (Loss) on Sale of Investments | - | - | - | -2.76 | - |
| Gain (Loss) on Sale of Assets | 0.13 | 0.13 | 0.08 | - | - |
| Pretax Income | 86.43 | 71.44 | 65.02 | 70.46 | 77.81 |
| Income Tax Expense | 5.99 | 5.61 | 5.57 | 4.18 | 5 |
| Net Income | 80.44 | 65.83 | 59.45 | 66.28 | 72.81 |
| Net Income to Common | 80.44 | 65.83 | 59.45 | 66.28 | 72.81 |
| Net Income Growth | 94.73% | 10.72% | -10.31% | -8.97% | - |
| Shares Outstanding (Basic) | 20 | 20 | 20 | 20 | 20 |
| Shares Outstanding (Diluted) | 20 | 20 | 20 | 20 | 20 |
| Shares Change (YoY) | -0.00% | - | - | - | - |
| EPS (Basic) | 4.02 | 3.29 | 2.97 | 3.31 | 3.64 |
| EPS (Diluted) | 4.02 | 3.29 | 2.97 | 3.31 | 3.64 |
| EPS Growth | 94.73% | 10.72% | -10.31% | -8.97% | - |
| Free Cash Flow | 41.84 | 71.82 | 58.99 | 25.28 | 11.42 |
| Free Cash Flow Per Share | 2.09 | 3.59 | 2.95 | 1.26 | 0.57 |
| Gross Margin | 63.00% | 61.18% | 60.61% | 60.50% | 58.15% |
| Operating Margin | 23.61% | 22.91% | 22.93% | 26.52% | 26.68% |
| Profit Margin | 20.78% | 19.45% | 19.64% | 23.08% | 24.14% |
| Free Cash Flow Margin | 10.81% | 21.22% | 19.49% | 8.80% | 3.78% |
| EBITDA | 100.35 | 85.14 | 76.25 | 82.86 | 87.19 |
| EBITDA Margin | 25.92% | 25.16% | 25.19% | 28.85% | 28.90% |
| D&A For EBITDA | 8.93 | 7.61 | 6.84 | 6.7 | 6.69 |
| EBIT | 91.42 | 77.53 | 69.41 | 76.16 | 80.49 |
| EBIT Margin | 23.61% | 22.91% | 22.93% | 26.52% | 26.68% |
| Effective Tax Rate | 6.93% | 7.85% | 8.57% | 5.93% | 6.43% |
Source: S&P Capital IQ. Standard template.
Financial Sources.